Abstract
Lynch syndrome is estimated to affect 1 out of every 279 individuals worldwide. However, 95% of individuals with Lynch syndrome are not aware of their diagnosis. Therefore, it is important that we maximize all possible efforts to diagnose individuals with Lynch syndrome. Universal tumor screening is one approach that has been successful in helping to identify patients who might not have been referred for a genetics assessment otherwise. Universal tumor screening consists of testing the paraffin-embedded tumor from individuals with colorectal or endometrial cancer for features of deficient mismatch repair including microsatellite instability and/or absence of any of the four mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2) using immunohistochemical (IHC) staining. Several professional organizations have recommended universal tumor screening of all newly diagnosed colorectal cancer patients at the time of diagnosis. Reasons for this recommendation are that patients whose tumors exhibit microsatellite instability (whether proven by MSI testing or extrapolated from abnormal IHC testing) have a better prognosis may need different treatment from those without microsatellite instability, and are more likely to have Lynch syndrome. Patients whose tumors exhibit MSI or have abnormal IHC without MLH1 methylation are suspicious for having Lynch syndrome and are candidates for genetic counseling and germline genetic testing. Best practices for implementing universal tumor screening have been explored.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev. 2017;26(3):404–12. https://doi.org/10.1158/1055-9965.EPI-16-0693.
American Cancer Society. Key statistics for colorectal cancer. 2016. http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics. Accessed 2 May 2016.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8. https://doi.org/10.1200/JCO.2008.17.5950.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60. https://doi.org/10.1056/NEJMoa043146.
Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H, et al. PS1-08: Lynch syndrome screening pattering in colorectal cancer patients in a large multi-institutional cohort. Clin Med Res. 2012;10(3):146.
Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42–65.
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–6.
Diaz LA Jr, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979. https://doi.org/10.1056/NEJMc1510353.
Recommendations from the EGAPP Working Group. Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109(8):1159–79. https://doi.org/10.1038/ajg.2014.186.
Referenced with permission from the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal V.1.2016 © National Comprehensive Cancer Network IArrAJ, https://www.nccn.org/store/login/login.aspx?
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.; ; quiz 63. https://doi.org/10.1038/ajg.2014.435.
Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2008;6(2):206–14. https://doi.org/10.1016/j.cgh.2007.10.011.
Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet. 2012;20(7):762–8. https://doi.org/10.1038/ejhg.2011.277.
Grosse SD. When is genomic testing cost-effective? Testing for Lynch syndrome in patients with newly-diagnosed colorectal cancer and their relatives. Health. 2015;3(4):860–78.
Grosse SD, Palomaki GE, Mvundura M, Hampel H. The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. Genet Med. 2015;17(6):510–1. https://doi.org/10.1038/gim.2015.53.
Gudgeon JM, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care. 2011;17(8):e288–300. doi:50524 [pii]
Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93–104.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess. 2014;18(58):1–406. https://doi.org/10.3310/hta18580.
Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69–79. https://doi.org/10.1059/0003-4819-155-2-201107190-00002. 155/2/69 [pii]
Severin F, Stollenwerk B, Holinski-Feder E, Meyer E, Heinemann V, Giessen-Jung C, et al. Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med. 2015;17(10):765–73. https://doi.org/10.1038/gim.2014.190.
Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. Am J Manag Care. 2012;18(5):e179–85.
Gould-Suarez M, El-Serag HB, Musher B, Franco LM, Chen GJ. Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Dig Dis Sci. 2014;59(12):2913–26. https://doi.org/10.1007/s10620-014-3248-6.
Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, et al. Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns. 2012;21(4):484–93. https://doi.org/10.1007/s10897-011-9465-7.
Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33(2):209–17. https://doi.org/10.1200/JCO.2014.58.1322.
Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S, et al. Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ. 2017;356:j1388. https://doi.org/10.1136/bmj.j1388.
Balmana J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. AnnOncol: Off J EurSocMed Oncol/ESMO. 2013;24(Suppl 6):vi73–80. https://doi.org/10.1093/annonc/mdt209.
Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for lLynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30(10):1058–63. JCO.2011.38.4719 [pii] 31.1200/JCO.2011.38.4719
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596.
Cragun D, DeBate RD, Vadaparampil ST, Baldwin J, Hampel H, Pal T. Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genet Med. 2014;16(10):773–82. https://doi.org/10.1038/gim.2014.31.
Cragun D, Pal T, Vadaparampil ST, Baldwin J, Hampel H, DeBate RD. Qualitative comparative analysis: a hybrid method for identifying factors associated with program effectiveness. J Mixed Methods Res. 2016;10(3):251–72. https://doi.org/10.1177/1558689815572023.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci: IS. 2009;4:50. https://doi.org/10.1186/1748-5908-4-50.
Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U. Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11(9):1093–100. https://doi.org/10.1016/j.cgh.2013.04.044.
Stoffel EM, Ford B, Mercado RC, Punglia D, Kohlmann W, Conrad P, et al. Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol. 2008;6(3):333–8. https://doi.org/10.1016/j.cgh.2007.12.014.
Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol. 2005;16(4):428–33.
Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38(11):1501–9. https://doi.org/10.1097/PAS.0000000000000321.
Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. Scand J Gastroenterol. 2011;46(11):1340–8. https://doi.org/10.3109/00365521.2011.610003.
Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2012;118(3):681–8. https://doi.org/10.1002/cncr.26323.
Trano G, Sjursen W, Wasmuth HH, Hofsli E, Vatten LJ. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br J Cancer. 2010;102(3):482–8. https://doi.org/10.1038/sj.bjc.6605509.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2016;3(4):464–71. https://doi.org/10.1001/jamaoncol.2016.5194.
Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013;31(10):1336–40. https://doi.org/10.1200/JCO.2012.45.1674.
Hampel H, Lattimer I, Frankel W. Universal Lynch syndrome screening result notification: efficacy affected by method. J Genet Couns. 2012;21(6):888–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Hampel, H., Pearlman, R., Cragun, D. (2018). Universal Tumor Screening for Lynch Syndrome. In: Valle, L., Gruber, S., Capellá, G. (eds) Hereditary Colorectal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-74259-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-74259-5_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74258-8
Online ISBN: 978-3-319-74259-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)